You are here:
26 April 2021 / deal

Lauxera Capital Partners invests in LUMICKS

LUMICKS, a leading, next generation life science tools company that develops highly innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announced the completion of a $93 million Series D preferred share financing.

Lauxera Capital Partners invests in LUMICKS

The funding round was led by new investors Farallon Capital Management and Lauxera Capital Partners, and included investments by Softbank Vision 2i, funds and accounts advised by T. Rowe Price Associates, Parian Global Management, Pura Vida Investments, and Irving Investors. The round was also backed by existing investor Gilde Healthcare and select members of the LUMICKS management team. A majority of the proceeds from the financing will be used to bolster growth initiatives including expansion of both research and development and commercial activities for the z-MoviĀ® Cell Avidity Analyzer.



Yucaipa Acquisition Corporation on USD 3.2 billion deSPAC merger with SIGNA Sports United

YAC on USD 3.2 billion deSPAC merger with SIGNA Sports United

The combination also includes the acquisition of the WiggleCRC Group, currently owned by Bridgepoint. read more
Wallbox in USD 1.5 billion deSPAC merger and NYSE listing

Wallbox in USD 1.5 billion deSPAC merger and NYSE listing

Wall Box Chargers, S.L. (Wallbox) and Kensington Capital Acquisition Corp. II have announced a definitive agreement for a business combination. read more
Genoteerd - Spoedprocedures in overnameprocessen

Quoted - Expedited proceedings in takeover processes

The relevant differences between inquiry proceedings and summary proceedings as a means of initiating expedited proceedings in takeover processes. read more